Two common drugs do not increase spontaneous vaginal births in first-time mums

There is no clear evidence that hyoscine butylbromide or sodium bicarbonate improve spontaneous vaginal birth rates (without the assistance of forceps or vacuum) in first-time mums after induction of labor, finds a large Norwegian trial published by The BMJ today.

Although small benefits of either drug can't be entirely ruled out, the researchers say the findings do not support their routine use.

Women having their first baby after induction of labor have relatively high rates of instrumental and caesarean delivery. Small studies have proposed that hyoscine butylbromide, by relaxing the cervix, and sodium bicarbonate, by improving muscle function, may promote spontaneous vaginal birth.

However, these studies have limitations, and no previous trial has evaluated both drugs after induction of labor and their effects on spontaneous vaginal birth.

To address this, researchers identified 2,963 first-time mums (average age 31 years) due to give birth to a single baby at term and undergoing labor induction at 11 hospitals across Norway between 4 January 2023 and 29 January 2025.

At the onset of active labor, women were randomly assigned to one of four groups: oral sodium bicarbonate plus intravenous hyoscine butylbromide, oral sodium bicarbonate plus intravenous placebo, oral placebo plus intravenous hyoscine butylbromide, or double placebo.

The drugs were repeated every four hours to a maximum of three doses. The main outcome was spontaneous vaginal birth without instrumental or caesarean delivery.

Spontaneous vaginal birth occurred in 57% (422 of 741) in the bicarbonate plus hyoscine butylbromide group, 61% (445 of 734) in the bicarbonate group, 61% (449 of 741) in the hyoscine butylbromide group, and 56% (422 of 747) in the double placebo group. 

None of these differences reached the prespecified threshold for statistical significance. However, the authors note that smaller beneficial effects on spontaneous vaginal birth can't be entirely excluded.

Serious adverse events were similar between groups, and no treatment-related serious illness was observed.

The authors acknowledge certain trial limitations. For example, drugs were administered at the onset of active labor irrespective of early labor progression and participants who were not proficient in Norwegian or English were excluded, which may limit generalizability.

However, they say this was a large, nationwide trial where participants, clinical staff, investigators, and outcome assessors were all masked to treatment groups, minimizing the risk of bias, and results were consistent after further analyses, suggesting that they are robust.

As such, they conclude: "Neither agent, alone or in combination, clearly increased spontaneous vaginal birth, although small beneficial effects of either agent could not be excluded. The findings do not support routine intrapartum use of hyoscine butylbromide or sodium bicarbonate after induction of labor."

Source:
Journal reference:

Michelsen, T. M., et al. (2026). Effect of intrapartum hyoscine butylbromide and sodium bicarbonate on spontaneous vaginal birth in nulliparous women after induction of Labour (SAINT): Multicentre randomised placebo controlled factorial trial. BMJ. DOI: 10.1136/bmj-2026-101069. https://www.bmj.com/content/395/bmj-2026-101069

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Why addiction researchers are paying closer attention to GLP-1 drugs